Terra Innovatum is Accelerating Plans to Advance its Strategic Position in the Rapidly Growing Radioisotope Market by Producing Life-Saving Cancer Isotopes
Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (Nasdaq: GSRT), a publicly traded special purpose acquisition company, today announced that it has accelerated its go-to-market plans for life-saving cancer isotope production with the SOLO™ micro-modular reactor.
According to the World Nuclear Association, over 10,000 hospitals worldwide use radioisotopes in medicine1 with reports estimating that the nuclear radioisotope market will grow annually from $7 billion in 2025 to $11.68 billion by 20302.
Terra Innovatum is developing collaborative business models and frameworks to engage with leading isotope producers and distributors such as NorthStar, ANSTO, BWXT Medical, IRE, NRG, NTP Radioisotopes, and Nordion to broaden access, strengthen partnerships, and expand global market reach.
Press Release Reference Links:
Nasdaq MarketSite
GlobeNewswire